0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Other Articles |

Contraceptive Tablets

Robert W. Kistner, M.D.
JAMA. 1962;179(7):583. doi:10.1001/jama.1962.03050070105023.
Text Size: A A A
Published online

ABSTRACT

To the Editor:—  I have read with interest the reply of Dr. Beecham in the Questions and Answers section of The Journal (178:95 [Oct. 7] 1961) regarding the side effects of norethynodrel with ethynylestradiol 3-methyl ether (Enovid) used as a contraceptive. I think that 2 important points were made in regard to stromal hyperplasia and increased growth of uterine fibroids with norethynodrel with ethynylestradiol 3-methyl ether.Dr. Beecham quoted the communication of Dockerty, Smith, and Symmonds, published in the Proceedings of the Mayo Clinic in 1959 in which the problem of stromal hyperplasia was first mentioned. Dockerty has subsequently stated that any qualified pathologist should be able to interpret the unusual endometrial changes induced by these newer agents. It is believed that a number of general pathologists "over-diagnosed" the endometrial changes and that no valid correlation has been shown with sarcoma. Furthermore, no evidence is available to indicate that

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();